Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 22, 2022 - Issue 1
Submit an article Journal homepage
755
Views
4
CrossRef citations to date
0
Altmetric
Systematic Review

Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis

Matteo Santonia Oncology Unit, Macerata Hospital, Macerata, ItalyView further author information
,
Alessandro Rizzob Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ItaliaView further author information
,
Veronica Mollicab Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ItaliaView further author information
,
Matteo Rosellinib Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ItaliaView further author information
,
Andrea Marchettib Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ItaliaView further author information
,
Benedetta Fragomenob Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ItaliaView further author information
,
Nicola Battellia Oncology Unit, Macerata Hospital, Macerata, ItalyView further author information
&
Francesco Massarib Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ItaliaCorrespondence[email protected]
View further author information
 show all
Pages 45-51 | Received 30 Mar 2021, Accepted 27 May 2021, Published online: 15 Jun 2021

References

  • Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.
  • Santoni M, Buti S, Conti A, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 2015;10(4):517–522.
  • Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–366.
  • Brown LC, Desai K, Zhang T, et al. The immunotherapy landscape in renal cell carcinoma. BioDrugs. 2020;34:733–748.
  • Chowdhury N, Drake CG. Kidney cancer: an overview of current therapeutic approaches. Urol Clin North Am. 2020;47:419–431.
  • Massari F, Mollica V, Rizzo A, et al. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19:1329–1338.
  • Rini BI, Battle D, Figlin RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019;7:354.
  • Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:706–720.
  • Motzer RJ, Rini BI, McDermott DF, et al. CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20:1370–1385.
  • Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–1127.
  • Choueiri TK, Powles T, Burotto M, et al. 696O_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. Ann Oncol. 2020;31(suppl_4):S1142–S1215.
  • Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Eng J Med. 2021;384:1289–1300.
  • Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5:e001079.
  • Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21:1563–1573.
  • Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–137.
  • Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75:799–810.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.